alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
lO. BOX 12308, CAPITOLSTATION AUSTIN, TEXAS 78711 

### OFFICIAL BUSINESS STATE OF TEXAS PENALTY FOR 

## PRIVATE USE

RE: WR-82,030-01 

# ^P0%

•1 ' tS&SP^B =? PITNEY SOWIiS 

# ^u, ir $0Q.406 £jj.f? 0006557438 JAN13 2015 S3 MAILED FROM ZIPCODE 78 701
**T T**  IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 22 - 0 635 STATE OF MONTANA,

Plaintiff and Appellee , v. SAUL JAMES DOOLING ,

Defendant and Appellant .

**GRANT OF EXTENSION** Upon consideration of Appellee’s motion for a 30 - day extension of time, and good cause appearing therefor, Appellee is granted an extension of time to and including July 15 , 2024 , within which to prepare, file, and serve the State’s response brief

.

Electronically signed by: Bowen Greenwood Clerk of the Supreme Court June 11 2024

06/11/2024

Case Number: DA 22-0635
EXHIBIT 11

                        SURGICAL LASER TECHNOLOGIES, INC.
                                AND SUBSIDIARIES
                  COMPUTATION OF EARNINGS PER SHARE (UNAUDITED)
                      (In thousands, except per share data)

<TABLE>
<CAPTION>
                                                                                       For the Quarter Ended:
                                                                                   March 30, 1997   March 31, 1996
<S>                                                                                <C>              <C>
Primary Loss Per Common Share:
Net loss                                                                              $  (197)        $  (820)

Weighted average number of shares of Common Stock outstanding during
  the period                                                                            9,882           9,854
Additional shares assuming exercise of stock options and warrants utilizing
  the treasury stock method                                                              --              --
                                                                                      -------         -------

Weighted average Common Stock and Common Stock equivalents outstanding                  9,882           9,854
                                                                                      =======         =======

Primary loss per share                                                                $ (0.02)        $ (0.08)
                                                                                      =======         =======

Fully Diluted Loss per Common Share:
  Net loss                                                                            $  (197)        $  (820)

Weighted  average  number of shares of Common  Stock  outstanding  during  the
  period                                                                                9,882           9,854
Additional  shares assuming  exercise of stock options and warrants  utilizing
  the treasury stock method                                                              --              --
Additional shares assuming conversion of convertible subordinated notes                  --              --
                                                                                      -------         -------

Weighted average Common Stock and Common Stock equivalents outstanding
                                                                                        9,882           9,854
                                                                                      =======         =======

Fully diluted loss per share                                                          $ (0.02)        $ (0.08)
                                                                                      =======         =======
</TABLE>


                                       11
<PAGE>
<PAGE>

                                                                    Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Indevus Pharmaceuticals, Inc. (the
"Company") on Form 10-Q for the period ended December 31, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Glenn
L. Cooper, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of my knowledge: (1) The Report fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

                                         By: /s/ Glenn L. Cooper
                                             -------------------------------
                                             Chief Executive Officer
                                             February 14, 2003

                                       22
Quinton PETERSON, petitioner, v. WEST VIRGINIA.

No. 17-5804.

Supreme Court of the United States

Jan. 8, 2018.

*644Petition for writ of certiorari to the Supreme Court of Appeals of West Virginia denied.
Carolyn BAILEY, petitioner, v. ZUCKER, GOLDBERG & ACKERMAN, LLC, et al.

No. 17-33.

Supreme Court of the United States

Nov. 27, 2017.

Petition for rehearing denied.
Lori ZELTWANGER v. U.S. BANK NATIONAL ASSOCIATION.

No. 17-553 (R46-008/OT 2017).

Supreme Court of the United States

Dec. 15, 2017.

The petition for writ of certiorari was dismissed today pursuant to Rule 46.1 of the Rules of this Court.
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

JORGE EZEQUIEL VALDEZBONILLA,

 Petitioner,

 v.

ERIC H. HOLDER, Jr., Attorney General,

 Respondent.

No. 09-72240

Agency No. A099-469-546

MEMORANDUM*

On Petition for Review of an Order of the

Board of Immigration Appeals

Submitted February 15, 2011** 

Before: CANBY, FERNANDEZ, and M. SMITH, Circuit Judges.

Jorge Ezequiel Valdez-Bonilla, a native and citizen of El Salvador, petitions

for review of the Board of Immigration Appeals’ (“BIA”) order dismissing his

appeal from an immigration judge’s decision denying his application for asylum,

withholding of removal, and relief under the Convention Against Torture (“CAT”). 

FILED

MAR 08 2011

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2

We have jurisdiction under 8 U.S.C. § 1252. We review de novo questions of law,

Cerezo v. Mukasey, 512 F.3d 1163, 1166 (9th Cir. 2008), except to the extent that

deference is owed to the BIA’s determination of the governing statutes and

regulations, Simeonov v. Ashcroft, 371 F.3d 532, 535 (9th Cir. 2004). We review

for substantial evidence factual findings. Zehatye v. Gonzales, 453 F.3d 1182,

1184-85 (9th Cir. 2006). We deny the petition for review.

We reject Valdez-Bonilla’s claim that he is eligible for asylum and

withholding of removal based on his membership in a particular social group,

namely, victims of gang recruitment. See Santos-Lemus v. Mukasey, 542 F.3d 738,

744-46 (9th Cir. 2008) (rejecting as a particular social group “young men in El

Salvador resisting gang violence”); Ramos-Lopez v. Holder, 563 F.3d 855, 860-62

(9th Cir. 2009) (rejecting as a particular social group “young Honduran men who

have been recruited by [a gang], but who refuse to join”). Valdez-Bonilla’s social

visibility argument is foreclosed by our decision in Santos-Lemus, 542 F.3d at 744-

46. 

Substantial evidence supports the agency’s denial of Valdez-Bonilla’s CAT

claim because he failed to show it is more likely than not that he will be tortured if

he returns to El Salvador. See id. at 747-48. 
3

Finally, we reject Valdez-Bonilla’s claim under the William Wilberforce

Trafficking Victims Protection Reauthorization Act of 2008 (“TVPRA”), Pub. L.

110-457, because he is not eligible for relief. See 6 U.S.C. § 279(g)(2)(C)(i). 

PETITION FOR REVIEW DENIED.
# Official Journal C 160/30 J

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 160 |
| | |
| English edition | Information and Notices | Volume 4830 June 2005 |

ISSN 1725-2423

Official Journal

of the European Union

C 160

English edition

Information and Notices

Volume 4830 June 2005

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Council |
| 2005/C 160/1 | Convention on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the Convention on the elimination of double taxation in connection with the adjustment of profits of associated enterprises | 1 |
| 2005/C 160/2 | Minutes of the signing of the Convention on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the Convention on the elimination of double taxation in connection with the adjustment of profits of associated enterprises | 11 |

Notice No

Contents

page

I   Information

Council

2005/C 160/1

Convention on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the Convention on the elimination of double taxation in connection with the adjustment of profits of associated enterprises

1

2005/C 160/2

Minutes of the signing of the Convention on the accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the Convention on the elimination of double taxation in connection with the adjustment of profits of associated enterprises

11

---

| EN | |
| --- | --- |

EN
In Re Lakesha NORINGTON, petitioner.

No. 17-6648.

Supreme Court of the United States

Jan. 8, 2018.

Petition for writ of mandamus and/or prohibition denied.
# CE2004065EN.01027001.xml

| 13.3.2004 | EN | Official Journal of the European Union | CE 65/270 |
| --- | --- | --- | --- |

13.3.2004

EN

Official Journal of the European Union

CE 65/270

---

(2004/C 65 E/283)

WRITTEN QUESTION P-3154/03

by Michael Cashman (PSE) to the Commission

(20 October 2003)

Subject:   Mobile telephone safety

Subject:

Given the findings of recent studies which show that the new generation of mobile telephones can interfere with many types of heart pacemaker, can the Commission detail what measures are being taken to prevent harm to the health of EU citizens?

It would seem that newer pacemakers that are fitted with a ceramic filter are immune. Can the Commission confirm that steps are being taken to introduce these models across the industry and to ensure that the public are aware of the risks of using the old models?

Can the Commission also detail what information it has provided regarding the safety of using mobile telephones in conjunction with a pacemaker since 1994?

Answer given by Mr Liikanen on behalf of the Commission

(3 November 2003)

(3 November 2003)

The Commission is collecting the information it needs to answer the question. It will communicate its findings as soon as possible.

---
Exhibit 31.b

I, Marc N. Teal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Boston Capital Tax Credit Fund II Limited Partnership (the "Partnership");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



1. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
2. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
3. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and





1. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



1. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
2. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



|Date: November 19, 2007 | /s/ Marc N. Teal                     
|----------------------- | -------------------------------------
|                        | Marc N. Teal, Chief
Financial Officer



69
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   12-Mos
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-01-1999
<PERIOD-END>                                   DEC-31-1999
<CASH>                                         41,127
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                   100,435
<PP&E>                                             905,277
<DEPRECIATION>                                     141,546
<TOTAL-ASSETS>                                   1,779,302
<CURRENT-LIABILITIES>                            1,009,781
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                             4,185
<OTHER-SE>                                         510,897
<TOTAL-LIABILITY-AND-EQUITY>                    32,699,465
<SALES>                                             49,711
<TOTAL-REVENUES>                                    48,578
<CGS>                                            1,699,863
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  22,782
<INCOME-PRETAX>                                 (1,721,523)
<INCOME-TAX>                                    (1,721,523)
<INCOME-CONTINUING>                             (1,721,523)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (1,721,523)
<EPS-BASIC>                                          (0.04)
<EPS-DILUTED>                                        (0.04)



</TABLE>
[Federal Register Volume 87, Number 79 (Monday, April 25, 2022)]
[Notices]
[Page 24325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-08722]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; longitudinal and peripheral AD biomarkers in a diverse cohort 
of subjects.
    Date: June 1, 2022.
    Time: 9:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Maurizio Grimaldi, MD, Ph.D., Scientific Review 
Officer, National Institute on Aging, National Institutes of Health, 
7201 Wisconsin Avenue, Room 2C218, Bethesda, MD 20892, 301-496-9374, 
<a href="/cdn-cgi/l/email-protection#1473667d797578707d79265479757d783a7a7d7c3a737b62"><span class="__cf_email__" data-cfemail="a3c4d1cacec2cfc7cace91e3cec2cacf8dcdcacb8dc4ccd5">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: April 20, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-08722 Filed 4-22-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 32.2

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the
undersigned officer of Nautilus, Inc., a Washington corporation (the Company), does hereby certify that:

To my knowledge, the Annual Report on
Form 10-K for the year ended December 31, 2008 (the Form 10-K) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the
Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.



|               |  |  |  |     |  |                     |  |                        
|-------------- |  |  |  | --- |  | ------------------- |  | -----------------------
|March 16, 2009 |  |  |  | By: |  | /s/ Kenneth L. Fish
|Date           |  |  |  |     |  |                     |  | Kenneth L. Fish,       
|               |  |  |  |     |  |                     |  | Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the
Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Direct and Indirect Subsidiaries of Royal Invest InternationalCorp.

|  Company Name                                                     |  Parent Company                        |  Country of      Incorporation |
|------------------------------------------------------------------------|---------------------------------------------|-------------------------------------|
| Royal Invest Europe      B.V.                                          |  Royal Invest      International Corp. |  The      Netherlands          |
| Royal Invest      Development and Services B.V.                        |  Royal Invest      International Corp. |  The      Netherlands          |
| Vastgoed Beleggings      Mij. Bunnik 1 B.V.                            |  Royal Invest      International Corp. |  The      Netherlands          |
| Royal Invest German      Properties 1 B.V. (formerly Rico Staete B.V.) |  Royal Invest      Europe B.V.         |  The      Netherlands          |
| AlfangB.V.                                                             |  Royal Invest      Europe B.V.         |  The      Netherlands          |
| AmogB      B.V.                                                        |  Royal Invest      Europe B.V.         |  The      Netherlands          |
ACTV, INC. AND SUBSIDIARIES
                          COMPUTATION OF LOSS PER SHARE

<TABLE>
<CAPTION>
                                                      Six Month Period               Three Month Period
                                                        Ended June 30,                  Ended June 30,
                                                     1998            1999            1998           1999
                                                     ----            ----            ----           ----
<S>                                              <C>             <C>             <C>             <C>
Weighted average shares outstanding ..........     17,219,660      35,859,875      18,371,395      39,711,671

Common stock equivalents .....................             --              --              --              --
                                                 ------------    ------------    ------------    ------------
         Total ...............................     17,219,660      35,859,875      18,371,395      39,711,671
                                                 ============    ============    ============    ============

Net loss applicable to common shareholders ...   $ (6,035,538)   $(12,982,289)   $ (3,263,401)   $ (5,601,821)
                                                 ============    ============    ============    ============

Basic and diluted loss per share .............   $       (.35)   $       (.36)   $       (.18)   $       (.14)
                                                 ============    ============    ============    ============
</TABLE>


                                       16